In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
- 1 January 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (1) , 101-102
- https://doi.org/10.1097/00002030-200001070-00019
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapyProceedings of the National Academy of Sciences, 1998
- Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide ClassJournal of Medicinal Chemistry, 1998
- In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesAntimicrobial Agents and Chemotherapy, 1997
- Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorAntimicrobial Agents and Chemotherapy, 1997